España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Myriad Genetics
MYGN
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$12.67
-0.24
-1.86%
At close: -
$12.70
0.03
0.24%
After Hours: 5:44 PM EDT
Get Report
Comment
Myriad Genetics (MYGN) Forecast
News
Earnings
Myriad Genetics (MYGN) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Myriad Genetics (NASDAQ:MYGN) Stock
Myriad Genetics Stock (NASDAQ: MYGN)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, January 30, 2025
Piper Sandler Maintains Neutral on Myriad Gen...
Benzinga Newsdesk
Wednesday, January 29, 2025
Myriad Genetics Announces Prenatal DNA Screen...
Benzinga Newsdesk
Tuesday, January 28, 2025
Goldman Sachs Maintains Buy on Myriad Genetic...
Benzinga Newsdesk
Tuesday, January 21, 2025
Myriad Genetics Announces Publication Of Here...
Benzinga Newsdesk
Thursday, January 16, 2025
Demystifying Myriad Genetics: Insights From 6 Analyst Reviews
Benzinga Insights
Stephens & Co. Reiterates Equal-Weight on Myr...
Benzinga Newsdesk
Wednesday, January 15, 2025
Myriad Genetics Sees FY25 Adj. EPS $0.07-$0.1...
Benzinga Newsdesk
Myriad Genetics Sees Prelim. Q4 Adj. EPS $0.0...
Benzinga Newsdesk
Friday, January 10, 2025
Reported Earlier, Myriad Genetics Signs Agree...
Benzinga Newsdesk
Tuesday, January 07, 2025
The University Of Texas MD Anderson Cancer Ce...
Benzinga Newsdesk
Friday, December 13, 2024
B of A Securities Maintains Underperform on M...
Benzinga Newsdesk
Wednesday, December 11, 2024
Reported Earlier, Myriad Genetics Engages Uni...
Benzinga Newsdesk
Tuesday, December 10, 2024
UBS Initiates Coverage On Myriad Genetics wit...
Benzinga Newsdesk
Monday, December 09, 2024
Myriad Genetics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Benzinga Insights
This AMD Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Avi Kapoor
Myriad Genetics Announces NCCN Prostate Cance...
Benzinga Newsdesk
Leerink Partners Downgrades Myriad Genetics t...
Benzinga Newsdesk
Wednesday, November 20, 2024
Myriad Genetics Announces The Incorporation O...
Benzinga Newsdesk
Monday, November 18, 2024
Where Myriad Genetics Stands With Analysts
Benzinga Insights
Morgan Stanley Maintains Equal-Weight on Myri...
Benzinga Newsdesk
Monday, November 11, 2024
Piper Sandler Maintains Neutral on Myriad Gen...
Benzinga Newsdesk
Thursday, November 07, 2024
Myriad Genetics Q3 2024 Adj. EPS $0.06 Beats ...
Benzinga Newsdesk
Myriad Genetics Raises FY2024 Adj EPS Guidanc...
Benzinga Newsdesk
Monday, November 04, 2024
Myriad Genetics Was Informed On Friday, Novem...
Benzinga Newsdesk
Friday, November 01, 2024
Crude Oil Moves Higher; Apple Shares Slide After Q4 Results
Avi Kapoor
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results
Avi Kapoor
Wednesday, October 09, 2024
Myriad Genetics Reaffirms Previously Issued F...
Benzinga Newsdesk
Myriad Genetics Discloses Certain Preliminary...
Benzinga Newsdesk
Tuesday, October 08, 2024
Myriad Genetics Reveals Series Of Ongoing Res...
Benzinga Newsdesk
Thursday, October 03, 2024
Myriad Genetics And Ultima Genomics To Explor...
Benzinga Newsdesk
Tuesday, October 01, 2024
Myriad Genetics Says USPTO Issued Third Paten...
Benzinga Newsdesk
Thursday, September 19, 2024
Analyst Expectations For Myriad Genetics's Future
Benzinga Insights
Morgan Stanley Initiates Coverage On Myriad G...
Benzinga Newsdesk
Thursday, September 05, 2024
G-III Apparel Posts Upbeat Results, Joins NIO, Yext, Shoe Carnival And Other Big Stocks Moving Higher On Thursday
Avi Kapoor
Wednesday, September 04, 2024
Myriad Genetics shares are trading lower afte...
Benzinga Newsdesk
Myriad Genetics Said Due To Significant Dispa...
Benzinga Newsdesk
Tuesday, August 27, 2024
Wells Fargo Initiates Coverage On Myriad Gene...
Benzinga Newsdesk
Tuesday, August 20, 2024
Alcon's Market Share Gains, New Launches Aid Growth
Zacks
Tuesday, August 13, 2024
Should Quest Diagnostics be in Your Portfolio Now?
Zacks
Scotiabank Maintains Sector Outperform on Myr...
Benzinga Newsdesk
Myriad Genetics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Benzinga Insights
Piper Sandler Maintains Neutral on Myriad Gen...
Benzinga Newsdesk
Thursday, August 08, 2024
Myriad Genetics Q2 Earnings Surpass, '24 Outlook Raised
Zacks
Wednesday, August 07, 2024
TD Cowen Maintains Hold on Myriad Genetics, R...
Benzinga Newsdesk
JP Morgan Maintains Underweight on Myriad Gen...
Benzinga Newsdesk
Tuesday, August 06, 2024
Myriad Genetics Sees FY24 Gross Revenue $835M...
Benzinga Newsdesk
Myriad Genetics Q2 2024 Adj. EPS $0.05 Beats ...
Benzinga Newsdesk
Thursday, July 11, 2024
Myriad Genetics And Personalis Announce Cross...
Benzinga Newsdesk
Tuesday, July 09, 2024
Myriad Genetics Secures Second Patent To Enha...
Benzinga Newsdesk
Show More
